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Antibody-mediated rejection (AMR) is a major cause of late kidney transplant failure. It is important to have an understanding of
human-leukocyte antigen (HLA) typing including well-designed studies to determine anti-MHC-class-I-related chain A (MICA)
and antibody rejection pathogenesis. This can allow for more speciﬁc diagnosis and treatment which may improve long-term
graft function. HLA-speciﬁc antibody detection prior to transplantation allows one to help determine the risk for AMR while
detection of DSA along with a biopsy conﬁrms it. It is now appreciated that biopsy for AMR does not have to include diﬀuse C4d,
but does require a closer look at peritubular capillary microvasculature. Although plasmapheresis (PP) is eﬀective in removing
alloantibodies (DSAs) from the circulation, rebound synthesis of alloantibodies can occur. Splenectomy is used in desensitization
protocolsforABOincompatibletransplantsaswellasbeingfoundtotreatAMRrefractorytoconventionaltreatment.Alsousedare
agentstargetedforplasmacells,Bcells,andthecomplementcascadewhicharebortezomibrituximabandeculizumab,respectively.
1. UnderstandingHLA
There are 20 class I genes and in transplantation HLA-A,
B, and C are the classic genes referenced to when typing
the recipient [1]. Class I major histocompatibility complex
(MHC) molecule processing and loading of peptides occurs
in all nucleated cells, where class II MHC molecule involves
primarily B cells, macrophages, and dendritic cells by
method of endocytosis and phagocytosis. Class II MHC
moleculenomenclatureisdesignatedbyclass(D),family(M,
O, P, Q, R), and chain (A or B). Late antibody-mediated
rejection (AMR) is a major cause of late kidney transplant
failure and several developments in understanding of patho-
genesis allow for improvement of diagnosis, treatment, and
prevention. This review will concentrate on reviewing the
pathogenesis, diagnosis, and treatment of AMR.
2. Pathogenesis of HLAAntibodies
Not only can antibodies form against HLA molecules, but to
endothelial-cell antigens and across ABO blood group [2].
Sensitization prior to transplant can occur by pregnancy
or blood transfusions. Previous transplantation can also
sensitize patients against HLA molecules. Blood transfusions
can induce humoral immunity by formation of HLA alloan-
tibodies and are more likely to occur in individuals who have
been previously pregnant. Our understanding of how blood
transfusions cause sensitization is incomplete, but it is not
inevitable and can be attenuated by immunosuppression. In
a study performed by Eikmans et al. it was found two weeks
after blood transfusion in both nonsensitized and sensitized
recipients, increased numbers of IFN-γ-producing cells were
produced stimulating CD4+ and NK cells [3]. With de novo
HLA production, antibody rejection can occur within weeks
of the transplant. Endothelium of donor graft peritubular
andglomerularcapillariesdisplay MHCmoleculeswhichare
the target for antibody production. Once the endothelium
is damaged by antibody, von Willebrand factor and P-
selectinarereleasedasaninﬂammatoryresponse.Leukocytes
adhere to glomeruli or to dilated peritubular capillaries via
cytokines (IL-1 α, IL-8, and chemokine ligand 2) allowing2 Journal of Transplantation
complementactivation.Inantibodyrejection,C4disauseful
marker of complement activation and is seen commonly
in peritubular capillaries with proper immunohistochemical
staining technique. Chemoattractants C3a and C5a are a
part of the compliment cascade which activate C5b allowing
for assembly of membrane attack complex (MAC) which is
composed of C5b-C9. The MAC complex once activated will
cause local necrosis allowing detachment of endothelial cells
from the basement membrane, which is also a characteristic
ﬁnding upon biopsy indicative of AMR. If not treated prop-
erly in a timely manner, sequelae can include thrombotic
microangiopathy (TMA) causing hemorrhage with arterial
wall necrosis, and ultimately graft loss. Also potentially play-
ingaroleinAMRpathogenesisarepolymorphicMHC-class-
I-relatedchainA(MICA)antigens[4].Ithasbeenfoundthat
not all patients with AMR have anti-HLA antibodies, which
suggests other possible mechanisms involved in acute or
chronic graft damage. In a study conducted by Worthington
et al., only ﬁve out of 14 patients with renal graft dysfunction
and pathology showing C4d deposition in peritubular cap-
illaries were found to have anti-HLA antibodies [5]. MICA
antigens are structurally similar to MHC class I proteins,
closely linked to HLA-B and C loci [6]. MICA antigens can
be found on ﬁbroblasts, endothelial cells, dendritic cells,
and many tumors which unfortunately makes detection
diﬃcult by standard donor and recipient crossmatching.
MICA eplet repertoire has become the basis for developing
HLAMatchmaker program which analyzes antibody patterns
with single MICA alleles on Luminex platform. It has
been determined so far (Duquesnoy et al.) that there are
38 potentially immunogenic MICA eplets associated with
MICA-reactive serum [6]. MICA and HLA class I chains are
similar in conﬁguration however none of the polymorphic
residues are shared. HLAMatchmaker program is therefore
used to determine the speciﬁcity of anti-MICA antibodies
in sensitized patients since MICA is considered as a separate
alloantigenic system. In a study by Zhang et al., 52 patients
transplanted who were crossmatch negative were placed on
triple therapy (cyclosporine/tacrolimus, mycophenolate, and
prednisone). Once graft dysfunction was diagnosed with
positiveC4d,bothanti-HLAandanti-MICAantibodieswere
collected from serum and reviewed via Luminex. Of the
15 patients found to have anti-MICA antibodies, 9 patients
were positive for class I and/or class II anti-HLA antibodies.
Nine out of 15 patients were found to have C4d deposition,
and after reviewing patients for the follow-up period (1
year), it was found that eGFR decreased in anti-MICA and
anti-HLA antibody positive group. This study suggested
that patients with MICA antibodies have a more rapid
deterioration of graft function versus patients with just anti-
HLA antibodies. There are several proposed mechanisms
for anti-MICA antibody activation involving complement or
natural killer cells and studies are continuing to determine
the pathogenesis. A more thorough understanding of HLA
typing as well as continuing studies to determine anti-MICA
and antibody rejection pathogenesis may allow for novel
treatment strategies.
AMR occurs in up to 33% of cases undergoing ABO
incompatible kidney transplantation. Among cases in which
AMR is triggered in the early post-op period, prevalence
of transplant glomerulopathy is 22% at one year [7]. This
is opposed to the case in which Gloor found patients who
received desensitization to HLA antibodies showed more
glomerular changes versus ABO incompatible transplant
grafts not having clinical AMR, suggesting subclinical AMR
may exist [8]. The resistance of the graft to AMR in
spite of the presence of antibodies against donor endothe-
lium is called accommodation. There are several proposed
mechanisms to describe this phenomenon. One proposed
mechanism is a decrease in antigen-antibody interaction.
This is explained either by diﬀerence in antigen expression,
change in repertoire/level of antibodies in recipient, or
decreased susceptibility of injury to endothelium secondary
to continual stimulation of antibody and complement
components. It is proposed that continued stimulation of
endothelial cells by endotoxin or IL-1 over time diminishes
cellular responses to restimulation [7]. Another proposed
mechanism explaining accommodation could be a decrease
in the recipient’s type blood-type antigen on the endothe-
lium of the graft. Koestner et al. reported histo-blood type
change of a blood type B graft after ABO-mismatched
heart transplantation, where the recipient’s blood-type O
antigen was replaced by the donor’s type B antigen after
AMR graft loss [9]. The mechanism of replacement of
the recipient’s antigens remains unclear, and several studies
have been attempted to explain occurrence of blood-type
chimerism. One explanation is replacement of the recipient
type antigens by stem cells derived from injured vessel walls
after graft rejection. It is speculated that during AMR some
blood-type antigens could be shaved oﬀ from endothelial
surface from immunological reaction, resulting in loss of
blood-type antigens on the transplanted mismatched organ.
In addition the presence of diﬀuse C4d without capillary
damage or inﬂammation infers that accommodation may
include resistance to the terminal complement cascade.
There are some noted diﬀerences between HLA-sensitized
and ABO-incompatible renal transplantation in terms of
pattern of cell injury after C4d deposition. It has been found
that there is more graft loss with positive C4d AMR in
HLA-sensitized patients which may be due to diﬀerences in
biologicalresponsesbetweennon-self-carbohydrateantigens
(blood type antigens) and non-self-peptide antigens (HLA
antigens) [9].
3. Prevention
Crossmatchingnotonlyimproveslong-termgraftsurvivalby
identifying the presence of antidonor antibody in the recipi-
ent, but is used as a predictor of AMR [10]. Flow crossmatch
allows determination of positive T- or B-cell crossmatch
for transplantation. The donor cells are incubated with
the recipient serum, and antihuman globulin which is
ﬂuorescent dye tagged is placed in the ﬂow cytometer.
Positive T-cell crossmatch predicts rejection more accurately
than B-cell crossmatching. HLA-speciﬁc antibody detects
antibodies binding to individual HLA antigens and allowing
determination of antigens to avoid in a donor, coinedJournal of Transplantation 3
“unacceptable antigens” thus avoiding rejection. Of patients
who are highly sensitized, 30% can develop AMR [10]. HLA-
speciﬁc antibody detection prior to transplantation and
surveillance after transplantation during a rejection episode
allowsforavoidanceofrejectionanddeterminationofcourse
of treatment for AMR, respectively [11].
4.Diagnosis
The 1997 Banﬀ classiﬁcation was used to classify rejection
prior to the meeting in 2001, which further deﬁned patho-
logical classiﬁcation of AMR [12]. Gorer determined the
role of antibody after much debate in the early days of
transplantation,andunfortunatelyafterhisdeathin1961the
conceptofAMRwaslost.In1991-1992,FeuchtandHalloran
described C4d as a marker for AMR however this was not
uniformly utilized until the report from Solez et al. in 1998–
2000 [13]. After international transplant meetings in 1997,
AMR was an entity recognized by most of the participants
and C4d staining raised hope that morphological classiﬁ-
cation of AMR can be further deﬁned. Incidence of AMR
has been reported as 0–8% in renal transplant recipients in
larger centers largely due to increased recognition, detection
of DSA, retransplanted patients, as well as increase in
positive crossmatch and ABO incompatible transplantation
for highly sensitized patients. Colvin had reviewed studies
from Massachusetts General Hospital which for the ﬁrst
time indicated a clear correlation of peritubular capillary
C4d staining pathological features with DSA in AMR. A
few studies have indicated C4d staining is around 93–96%
speciﬁc, but 31–95% sensitive [12]. This raises a concern
that additional evidence is needed to diagnose AMR such
as quantiﬁcation of DSA or other morphologic feature
consistent with AMR on pathology. However it should be
noted that Regele and colleagues presented data from 1 year
after AMR that kidney transplant patients with positive C4d
had higher incidence of graft loss and elevation of serum
creatinine [14]. After the Banﬀ meeting in 2001 it was
determined that AMR has 3 cardinal features upon biopsy
ﬁndings.
(1) Acute tubular injury; neutrophils and/or mon-
onuclear cells in peritubular capillaries and/or
glomeruli, and/or capillary thrombosis; or arteri-
tis/ﬁbrinoid necrosis in the intima along with intra-
mural/transmural arterial inﬂammation.
(2) C4d evidence for antibody action and/or immuno-
globulin in peritubular capillaries, immunoglobulin
and complement in arterial ﬁbrinoid necrosis.
(3) Anti-HLA antibody (DSA) circulation in serum or
other antidonor endothelial antigens.
After the Banﬀ meeting in 2009, positive C4d deposition
without evidence of rejection was added to criteria suggest-
ing antibody-mediated changes. Several studies had reported
this ﬁnding including Mark Haas (Los Angeles) who had
seenC4ddepositioninbiopsieswithoutevidenceofrejection
[15]. In protocol biopsies from ABO incompatible grafts,
21/37 had C4d deposition without evidence of AMR lesions
or T-cell-mediated rejection which can suggest accommoda-
tion. Another addition to Banﬀ criteria indicating antibody-
mediated changes was determined to be positive C4d with
presence of circulating antidonor antibodies (no signs of
acute or chronic T-cell-mediated rejection or AMR/no ATN-
like minimal inﬂammation).
Innormalkidneys,speciﬁcallyintheglomerularmesang-
ium as well as arterioles at the vascular pole, turnover of
immune complexes occurs (C4d) [16]. Transplanted kidneys
in addition show deposition of C4d in peritubular capillaries
andcanfollowadynamiccourse.C4dcanbeinatransitional
state and show staining of only a few capillaries indicating
either an ongoing humoral attack or resolving previous
attack. There is sometimes diﬀuse staining in every capillary
or focal staining in only a few capillaries, but C4d is always
attached to endothelial cells and basement membranes.
There has also been evidence for C4d negative AMR in a
couple studies, which in the past few years has brought to the
forefrontthelimitationsofC4dasamarkerforAMR[17].In
one such study by Sis et al., overexpression of 12-individual
endothelial-associated transcripts genes (ENDATs) upon
transplant biopsies with graft dysfunction was correlated
with an increased risk of graft loss [18]. High ENDAT
expression and endothelial activation with DSA was found
to be strongly associated with the presence of transplant
glomerulopathy.Interestingly,fewerthan50%ofthebiopsies
performed (n = 173) with DSA and ENDATs had diﬀuse C4d
staining in peritubular capillaries. Investigators also have
found that C4d negative form of AMR is less severe than C4d
positive AMR but is associated with chronic changes within
the graft, such as transplant glomerulopathy. A possible
complement-independent mechanism of microcirculation
injury in AMR is plausible. It has been postulated that
DSA binding to endothelial cells triggers natural-killer
cells to release interferon-γ resulting in granule-associated
toxicity.
4.1. Monitoring of DSA. DSA has been found to play a role
in diagnosis of AMR and can be an independent predictor
of allograft loss [19]. It was found when patients had DSA
at time of clinical rejection diagnosed by Luminex, 50%
reduction in DSA within 14 days of diagnosis had higher
allograft survival. In a study performed by Everly et al., acute
rejection was deﬁned as an increase in serum creatinine by
20% above the baseline upon rejection; DSA was identiﬁed
by antigen bead panels by Luminex assay [19]. 650 patients
were analyzed for acute rejection, 94 of which were identiﬁed
with biopsy-proven acute rejection by Banﬀ criteria. Fifty-
two of these patients were found to have DSA present.
Analysis of predictors of allograft loss revealed DSA to be
an independent predictor of allograft loss, with a sixfold
increase in allograft loss rates. However, it is noted in this
study that DSA was present in the absence of C4d staining
onbiopsy.Furtherstudiesneedtobeconductedtodetermine
if complete elimination of DSA is necessary. However, from
this study it should be deduced that DSA reduction should
receive consideration as a potential therapeutic goal for
rejection therapy. Suppression of DSA with antihumoral4 Journal of Transplantation
therapies may provide a means for improving long-term
renal allograft survival. Bortezomib, a new anti-B-cell agent
that targets antibody producing cells (plasma cells) has
shown promise as an eﬀective means for reducing DSA as
well. It has also been postulated that surveillance of DSA
can be a means of preventing rejection, especially for highly
sensitized patients [20]. It has been discussed that high-risk
patients (presensitized and retransplants) may beneﬁt from
more DSA surveillance in the ﬁrst 3 months after transplant
to detect an early immune response; however this is not
rigorously proven to improve outcomes.
5. Treatment
5.1. Plasmapheresis, Immunoadsorption, and IVIG. Plasma-
pheresis (PP) removes alloantibodies from the circulation
and is the fastest and most eﬀective method for elimination
of DSA [11]. Usually 1.0–1.5 full-volume exchanges are
performed using albumin solution daily or alternate days,
continued until serum creatinine decreases 30% from the
baseline value. Although PP is eﬀective in removing alloan-
tibodies (DSA) from the circulation, rebound synthesis of de
novo alloantibodies can occur. IVIG is used in combination
with PP to neutralize antibodies and potentially block
complement activity as well as agents used for suppression
of antibody (cacineurin inhibitors, mycophenolate, or ritux-
imab).
Immunoadsorption (IA) is a substance derived from the
C o wanstraino fStaphylococcusaureus.TheproteinAcoating
the column beads has a strong aﬃnity for the Fc portion
of immunoglobulin and immune complexes [21]. For the
p a s td e c a d e ,p r o t e i nAI Aw a sf o u n dt or e m o v eh a r m f u l
antibodies and immune complexes eﬃciently and has been
used as treatment of AMR of highly sensitized patients. It
was found in a study by Qing et al. that classes I and II
panel-reactive antibody (PRA) as well as immunoglobulin
and complement (C3 and C4) were reduced signiﬁcantly.
However, it was found that within 6 to 8 hours rebound
of antibodies was seen. Previous studies have indicated
though that long-lasting favorable decrease in antibodies
persisted. It has been postulated that IA may cause a
conformation change of the structure of the antibodies and
immune complexes making them more immunogenic, and
immunostimulating to regulatory anti-idiotype antibodies.
These antibodies play a role in the control of autoimmune
mechanisms and reverse the continuing cycle of abnormal
immune balance. The long lasting response of IA therapy
may be explained by phagocytosis of the reticuloendothelial
system and activation of complement.
IVIG is prepared by human plasma from approximately
50,000–100,000 of healthy donors, composed of 90% intact
IgG, a few dimers, Fabs (fragment antigen-binding) and
traces of IgM and IgA [11]. there are many postulated
mechanisms of action of IVIG. The Fc region in IgG
allows it to interact and signal through Fc-gamma receptors
on phagocytes, B cells, and other cells as well as with
Fc-binding plasma proteins, such as components of the
complement system [20]. Immune globulin also prevents
damage mediated by immune complexes containing C3b
into an inactive form iC3b as well as neutralization of some
cytokines. IVIG can neutralize autoantibodies and down
regulate synthesis of antibodies by B cells expressing the
relevant idiotype. There are some studies with usage of IVIG
alone or in combination with PP, and when IVIG is used
alone a high dose is given (1-2g/kg). It was found IVIG was
eﬀective in reversing rejection within 2–5 days of infusion
with no recurrence in kidney transplant recipients [11]. The
usual recommended dose is 100mg/kg of IVIG after each PP
session and 300–400mg/kg for 1-2 days after the last PP with
a cumulative dose of 1000mg/kg. Various dosing schedules
are used, and the optimal dose has not been established. A
beneﬁt of IVIG is its ability to replenish gammaglobulin lost
during PP, decreasing infection risk. Adverse eﬀects of IVIG
which are common are headache, fever, chills, myalgias, and
hypotension/hypertension which can be reduced by slowing
the infusion rate. Serious adverse eﬀects are rare and can
include aseptic meningitis, acute renal failure, thrombotic
events, and anaphylaxis.
5.2. Antilymphocyte Therapy. Jin et al. had used Thymoglob-
ulin (ATG) 0.75mg/kg/day for 5–10 days in combination
with plasma exchange in 7 patients with AMR and showed
85% reversal in AMR [21]. ATG is a polyclonal preparation
generated from the immunization of rabbits with human
thymus. ATG eliminates CD4+ T-cell and B-cell interaction
causing B-cell toxicity/apoptosis and modulation of alloan-
tibody production. If both cellular and humoral features
are seen on biopsy, ATG is often used along with steroids
for treatment of AMR. ATG can be given in 3-4 doses to a
cumulative dose of 6mg/kg, and it is noted that leukopenia
is a side eﬀect which should be monitored to guide speciﬁc
treatment for each patient.
5.3. Splenectomy. The spleen is the largest lymphoid organ in
the body and has been found to play a role in alloantibody
generation. Splenectomy is used in desensitization proto-
cols for ABO incompatible transplants as well as positive
crossmatches, however it has been found to surprisingly
treat AMR refractory to treatment [22]. There are a few
case studies, one in particular where abundant clusters of
CD138+ plasma cells were found upon review of pathol-
ogy of the spleen [22]. Usually in traumatic splenectomy
controls, CD138+ cells are found in 1% of the spleen.
This patient had refractory AMR without improvement in
her serum creatinine. She had been treated with PP/IVIG
and then underwent emergent splenectomy. Immediately
afterward, there was improvement in her renal function and
rapid drop in DR51 antibodies [22]. The mechanism of
actionisnotentirelyclearastowhysplenectomytreatsAMR,
but several case reports have indicated that it could be a
potential treatment for refractory AMR to PP/IVIG. It is
not certain whether the CD138+ cells found in the spleen
had produced anti-DR51 antibodies in this particular case,
but provides a novel insight for further studies in the role
of the spleen with AMR. Of course, splenectomy has risks
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and the risks associated with surgery. Therefore these risks
must be discussed with the patient before proceeding, as this
is not a conventional treatment for AMR. There is lifelong
risk with encapsulated microorganisms; therefore patients
must receive Haemophilus inﬂuenza vaccine, pneumococcal,
and meningococcal vaccines.
5.4. Eculizumab. Most episodes of AMR are associated by
evidence of early complement activation by the presence
of C4d+ staining of the peritubular capillaries [23]. The
exact role of complement in the pathogenesis of AMR is still
being investigated. Eculizumab is a humanized monoclonal
antibody with high aﬃnity for C5 and blocks the activation
of terminal complement and is FDA approved for the
treatment of paroxysmal nocturnal hemoglobinuria. Serious
adverse eﬀects of this medication are an increased risk
of infections, particularly to encapsulated bacteria. It is
recommended to immunize patients at least two weeks
before the administration of eculizumab to meningococcus
and pneumococcus.
The transplant community is looking towards the use of
this medication because of its highly selective mechanism of
action [24]. There are several case reports using eculizumab
for desensitization before transplant and to treat AMR after
transplant. Stegall and colleges reported using eculizumab in
sensitized renal transplant recipients with high levels of DSA
to determine if the incidence of AMR in the ﬁrst 3 months
after transplant was decreased compared to historical con-
trols. These patients were immunized one month prior to
transplant, received plasmapheresis treatments before and
after transplant based on the crossmatch channel shifts, and
received the same induction and maintenance immunosup-
pression. The eculizumab dosing regimen included 600mg
on postoperative day 1, and 600mg weekly thereafter for 4
weeks. At week 4, assessment of DSA levels was performed
to determine if patients would continue treatment based
on DSA levels. The study found the incidence of AMR
was statistically signiﬁcanty lower in the eculizumab group
compared to the control group and reduced the need for
splenectomy,reducingtransplantglomerulopathy[25].Con-
sidering the cost of this medication, this dosing regimen and
prophylactic use might be unrealistic for smaller transplant
centers. A few case reports used eculizumab in treating renal
thrombotic microangiopathy (TMA) and reversal of com-
plement activation after ABO-incompatible transplantation
[26–28]. The use for TMA involved a patient whounderwent
a living related kidney transplant with a history of lupus
developed severe TMA, glomerular scarring, and diﬀuse
tubulointerstitial ﬁbrosis with positive aPL antibodies. The
patient received dialysis and plasmapheresis sessions with
no improvement in kidney function. The patient received
weekly infusions of eculizumab without complication and
renal function improved with subsequent biopsy revealed
complete resolution of TMA [26].
5.5. Bortezomib. The transplant community has recognized
the potential use of an agent that can directly target plasma
cells. Traditional treatments have been successful in remov-
ing antibodies, inhibiting antibody activity or lowering
pr oductionbutnotr eatmentsha v ebeeneﬀectiveintargeting
mature antibody production in plasma cells. AMR involves
the production of high levels of DSA by plasma cells either
newly made from memory or na¨ ıve B cells or from those that
existed prior to transplant. One mechanism to control AMR
is to target DSA production by plasma cells. Bortezomib
is a proteasome inhibitor which is FDA approved for the
treatment of multiple myeloma. This medication has been
shown to cause apoptosis of normal plasma cells which in
turn decreases alloantibody production in sensitized patients
[28].
Several case reports and series have been published
regarding the use of bortezomib. Currently available studies
of bortezomib for treatment of AMR are summarized in
Table 1. The University of Cincinnati reported the ﬁrst study
on the use of bortezomib in AMR. Everly and colleagues
treated six kidney transplant recipients with refractory AMR
and concomitant ACR with bortezomib and found fast
rejection reversal, reductions in DSA levels, improved renal
allograft function, and suppression of recurrent rejection
[29]. The same group reported two patients with AMR who
received bortezomib and these patients experienced prompt
AMR reversal and DSA elimination in 14 days [30]. The use
of bortezomib has also been published in ﬁve patients with
a combination of ACR and AMR. These patients were given
fourdosesofbortezomibandreversalofbothACRandAMR
occurred with reduction in DSA [30]. Other studies have
shown positive and mixed results regarding the use of this
medication in AMR and DSA levels [31, 32].
5.6. Rituximab. Rituximab is a chimeric anti-CD 20 (anti-B
cell)monoclonalantibodythatiscurrentlyFDAapprovedfor
the treatment of lymphoma. The CD 20 antigen is expressed
early in B-cell cycle but is absent on mature plasma cells.
The variable region of rituximab binds to CD 20 through
three diﬀerent mechanisms including antibody-dependent
cell cytotoxicity, complement-dependent cell killing, and
induction of apoptotic cell death. These mechanisms mark
cells for destruction and leads to sustained depletion of
circulating B cells [32, 33]. Genberg and colleagues reviewed
the pharmacodynamics after a single dose of rituximab given
to renal transplant patients and showed B-cell elimination
wasrapidandoccurredintheperipheralbloodover1-2days.
The eﬀect on the B-cell population was prolonged and did
not reemerge for 1 year and remained suppressed for 2 years
[34].
The ﬁrst report of using rituximab in AMR evaluated 27
patients with refractory rejection and received a single dose
of rituximab. Three grafts were lost and the remaining grafts
had good function at the time of discharge [35]. Kaposztas
and colleagues published a retrospective study involving 54
patients with AMR and were split into two groups. Group A
(n = 26) received plasmapheresis and rituximab and Group
B( n = 28) received plasmapheresis alone. Patients with low
serum IgG levels also received immunoglobulin. The two
year graft survival was signiﬁcantly better in the rituximab6 Journal of Transplantation
Table 1: Published studies of the use of bortezomib in AMR [11].
Study N Patients Treatment Outcome
Wade et al. 2009 [40]5Renal transplant with
mixed AMR and ACR
Bortezomib
1.3mg/m2/dose × 4
(i) Prompt AMR and ACR
reversal
(ii) Signiﬁcant decrease in
DSA levels
Tanriover et al. 2008 [38]6
Kidney/kidney pancreas
transplant with mixed
AMR and ACR
Same as above
(i) Prompt rejection
reversal marked and
prolonged reductions in
DSA levels
(ii) >50% decrease in DSA
levels within 14 days and
s u p p r e s s i o nf o ru pt o5
months
Celik et al. 2009 [37]2
Positive crossmatch renal
transplant recipient with
AMR
Bortezomib
1.3mg/m2/dose on days
1,4,8,11
Daily plasmapheresis and
IVIG
(i) Decrease HLA
allospeciﬁcities
(ii) Decrease in number of
plasma cells in bone
marrow
Faguer et al. 2010 [39]4
Renal transplant recipients
with AMR and persistently
elevated DSA
Bortezomib
1.3mg/m2/dose × 4
No signiﬁcant decrease in
DSA within 150 days post
treatment
Wade et al. 2009 [40]1 1
Living donor renal
transplant patients with
anti-HLA alloantibodies
Bortezomib
1.3mg/m2/dose with
methylprednisolone
250mg on days 1,4,8,11
2–4 sessions of
plasmapheresis 1 dose of
rituximab (6 patients)
(i) Reduced DSA and
non-DSA levels
(ii) Stable graft function 4
months post treatment
Faguer et al. 2010 [40]2 Living donor renal
transplant
Bortezomib
1.3mg/m2/dose × 4
Ongoing plasmapheresis,
rituximab, intravenous
steroids
(i) Immediate signiﬁcant
r e d u c t i o ni nD S A
(ii) Stable graft function at
6 months post treatment
group [36]. Since these two large case reports, there have
been many case series, and so forth published on using
rituximab with any of the studies for desensitization and for
AMR[37–40].Withmanyofstudiesthepatientpopulationis
small, with incomplete criteria for AMR diagnosis, and other
treatments used in conjunction with rituximab including
IVIG, plasmapheresis, and steroids. However it should be
noted in other studies particularly by Pescovitz, a small
number of patients failed to show a decrease in PRA with
rituximab alone [41].
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